Views & Analysis Future prospects for an Innovative Medicines Fund for Englan... On the 12 December 2019, the UK general public voted for a further five years of Conservative government.
News New price gets Clovis’ PARP inhibitor on the CDF NICE has reversed its decision on Clovis Oncology’s PARP inhibitor Rubraca (rucaparib) and will allow the drug to be used on the Cancer Drugs Fund (CDF), after the manufacturer offered a lower p
Views & Analysis NICE’s track record in cancer drugs: the impact of the CDF a... Leela Barham looks back to before the Cancer Drugs Fund and how recommendations have changed through CDF 1.0 and CDF 2.0 to explore it's success.
Views & Analysis Pharma’s new ‘sensible pricing’ behind cancer drug approvals... A string of 'yes' decisions from NICE on cancer drugs - but what has changed?
Debates & Insight Sponsored Finding a cure: Getting the best Brexit deal for Britain’s l... Four months have now elapsed since the UK voted to leave the EU.
Views & Analysis A novel UK approach to cancer access: yes, no, or maybe? Experts discuss the implications of the new, reinvigorated Cancer Drugs Fund, for pharma and patients.
R&D Modelling biologics: Challenges and opportunities, with Dr D... From AAPS 2025, an interview with Dr Dhaval Shah, professor of pharmaceutical sciences at the University of Buffalo and former Pfizer researcher.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.
